4.40Open4.40Pre Close36 Volume0 Open Interest7.50Strike Price16.11KTurnover275.61%IV0.64%PremiumOct 18, 2024Expiry Date4.38Intrinsic Value100Multiplier16DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type-0.8865Delta0.1088Gamma0.70Leverage Ratio-0.0098Theta-0.0022Rho-0.62Eff Leverage0.0013Vega
Sagimet Biosciences Stock Discussion
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in Mash
Sagimet Biosciences Inc. (Nasdaq: SCMT)
announced that the FDA has granted Breakthrough Therapy designation to denifanstat for treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
This designation was supported by positive data from the Phase 2b FASCINATE-2 trial, where denifanstat showed statistically significant imp...
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in Mash
Larger Image: tradingview.com...
$Sagimet Biosciences (SGMT.US)$
NEWS
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
In the fast-paced world of biotech investments, staying ahead of the curve is crucial for investors seeking substantial returns. Sagimet Biosciences (NASDAQ: SGMT), a company that has recently garnered significant attention from Leerink Partners, an esteemed investment firm, is one such entity that demands your immediate ...
No comment yet